This study shows that the antigenicity of Erwinia chrysanthemi Lasparaginase can be reduced by site-directed mutagenesis. Ten Bcell epitopes of the enzyme were identified using synthetic hexapeptides and polyclonal antisera from rabbits and mice. The region 282GIVPPDEELPG292 near the C-terminus was an immunodominant epitope. Binding of two hexapeptides (2831VPPDE288 and 287DEELPG292) to the antibodies was dependent on Pro285, and Pro286, since their replacement by almost any other amino acid resulted in reduced binding. The other residues were less important for binding the antibodies, as binding was relatively unaffected by amino acid substitutions.
INTRODUCTION
Interest in L-asparaginase (EC 3.5.1.1) has grown considerably since this enzyme was found to have anti-tumour activity (Kidd, 1953; Broome, 1961 Broome, , 1963 . The bacterial L-asparaginases from Erwinia chrysanthemi and Escherichia coli are effective in treating acute lymphoblastic leukaemia and lymphosarcoma, but their use against other forms of leukaemia or solid tumours is limited, since remissions are invariably of short duration (Wade and Phillips, 1971) . L-Asparaginase catalyses the hydrolysis of Lasparagine. Some tumour cells are deficient in L-asparagine synthetase and cannot synthesize sufficient L-asparagine. These cells are dependent on extracellular sources of the amino acid in order to complete protein synthesis (Keating et al., 1993) . They can therefore be destroyed by starving them of L-asparagine by the administration of L-asparaginase.
Treatment with the enzyme is often accompanied by toxic side effects, such as liver dysfunction and pancreatitis (Eden et al., 1990) . The enzymes from Vibrio succinogenes and guinea-pig serum lack hepatoxicity (Distasio et al., 1982) and do not possess L-glutaminase activity, suggesting that this activity in the Er. chrysanthemi and E. coli enzymes may be responsible for some of their toxic side effects. AAnotdier of the limiting factors of L- asparaginase treatment is the development of hypersensitivity, which ranges from mild allergic reactions to anaphylactic shock. The allergic reactions are normally treated by substitution with one of either the Er. chrysanthemi or the E. coli enzymes, as they show no immunological cross-reactivity (Hrushesky et al., 1976) .
The study of antigenic determinants has widespread importance in vaccine production, medical diagnostics and basic biological research (Goodman, 1989; Konrad, 1989; Stern, 1991) . Peptide-based assays for epitope mapping have been used ex- coli. The purified enzymes had subunit Mr values of 35000. The pI values of P285T, P286Q and the wild-type enzymes were 8.6, and that for the mutant E288A was 9.2. The kcat and Km values for the mutants P286Q and E288A with L-asparagine and L-glutamine were comparable with those ofthe wild-type enzyme.
The Km values for the mutant P285T with both substrates was similar to that of the wild-type enzyme, whereas the kcat was reduced by 2-fold with L-asparagine and by 4-fold with L-glutamine. The change proline -+ threonine reduced the antigenicity of the enzyme by 8-fold, as shown in sandwich e.l.i.s.a.s. using monoclonal antibodies raised against the wild-type enzyme.
tensively to identify antigenically important regions in proteins (Alexander et al., 1992) , although no attempts to reduce the antigenicity of a therapeutic protein have been reported. A combination of synthetic peptide analysis and site-directed mutagenesis have been used to modify the antigenicity of myohaemerythin (Alexander et al., 1992) . Residues that were identified as essential for antibody binding in peptide assays were also essential for antibody binding to the native protein.
One way of reducing the immunogenicity of a therapeutic protein is to covalently attach poly(ethylene glycol) derivatives. In the case of asparaginase this was found to reduce the immunogenicity in animal experiments (Abuchowski et al., 1984; Wada et al., 1990; Kodera et al., 1992 ). An alternative strategy to reduce the immune response would be to design a series of antigenically distinct, but catalytically similar, L-asparaginases. Treatment would involve the successive substitution of antigenically different forms of the enzyme to evade a strong immune response. This would decrease the allergic reactions associated with repeated use of the enzyme as well as expand the time over which the enzyme can be effectively administered. In this study the continuous epitopes of Er. chrysanthemi Lasparaginase were located by the binding of a set of overlapping synthetic peptides spanning the entire amino acid sequence to antibodies raised against the native enzyme. Residues within an immunodominant region that were essential for reduced binding of the peptides to the antibodies were identified using the replacement-net technique (Geysen et al., 1987 (Geysen et al., , 1988 . Those residues were further investigated by their replacement in the native protein. Three recombinant mutant enzymes P285T (proline-285 -+ threonine etc.), P286Q and E288A were constructed by site-directed mutagenesis and their catalytic and antigenic properties determined. (Geysen et al., 1987) .
MATERIALS AND METHODS Materials
Synthesis of a free peptide and peptide conjugation to carrier protein The peptide 282GIVPPDEELPG292 (C) of the L-asparaginase sequence was synthesized manually by Fmoc solid-phase chemistry (Merrifield, 1963) . The peptide was synthesized as a C-terminal amide using 4-(2',4-dimethoxyphenyl-Fmocaminoethyl)-phenoxy-resin. Cleavage from the resin was with 95 % (v/v) trifluoroacetic acid for 20 min at room temperature.
Characterization of the peptide was by reverse-phase h.p.l.c., with 98 % purity obtained. The peptide sequence was verified by fast-atom-bombardment m.s. (Wait et al., 1991) . The terminal cysteine residue was used for coupling the peptide to the carrier protein thyroglobulin by using m-maleimidobenzoyl-Nhydroxysuccinimide (Green et al., 1982) . Mouse polyclonal antibodies were raised using ug of the peptide-carrier conjugate. E.l.i.s.a. Three types of e.l.i.s.a were used to test the ability of antibodies to interact with different forms of the antigen.
(i) Screening of the rod-bound peptides. Polyethylene-bound the manufacturer's instructions for the epitope mapping kit (Cambridge Research Biochemicals, Cambridge, U.K.).
(ii) Indirect e.l.i.s.a.: binding of antibody to antigen-coated plates. Protein antigen was coated on to microtitre plates (Nunc Immunolon-2), using 100 ,u/well at a concentration of 5 ,ug/ml in coupling buffer (5mM Na2CO3/35 mM NaHCO3, pH 9.6), overnight at 4 'C. Alternatively, free peptide in PBS (8 mM Na2HP04/1.5 mM KH2PO4/137 mM NaCl/2.7 mM KC1, pH 7.4) was coated overnight at 37 'C and then fixed with methanol at room temperature for 10 min. The plates were washed twice between all subsequent incubations with 300,l of PBS, containing 0.1 % (v/v) Tween-20 per well. Residual binding sites were blocked for 1 h with 100,1 of supercocktail buffer
Serially diluted test antibody in PBS was added, incubated for 1-1.5 h, and the plates washed. The plates were incubated for a further 1 h with 100 ,u/well of horseradish peroxidase antispecific F(ab)2 conjugate and developed using 120,ul/well of freshly prepared 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulphonic acid) substrate solution [0.5 mg/ml in 0.03 % (v/v) H202/0.1 M Na2HP04/0.08 M citric acid, pH 4.0]. The A450 of the coloured product was determined using a Titertek Multiscan plate reader.
(iii) Sandwich e.l.i.s.a.: Binding of antibodies to ligandcaptured antigen. Purified monoclonal antibody raised against the wild-type enzyme was coated on to microtitre plates at 5 ,g/ml in coupling buffer (100 ,l/well) by incubation overnight at 4 'C. After the washing~and blocking steps the wells were incubated for 1-1.5 h with serially diluted test antigen (100 l/ well; 0-20 ng/ml). The bound antigen was detected with an optimized concentration of polyclonal antiserum (1: 500) raised against the wild-type enzyme. The e.l.i.s.a. was then continued as described above for the indirect e.l.i.s.a.
Construction of the L-asparaginase expression vector and site-directed mutagenesis
The plasmid expression vector containing the L-asparaginase gene pASN400 was kindly provided by Mr. I. R. Wilkinson of this Division. The vector was derived by deleting the 2.3 kb fragment (BamHl/Nrul) of pASN326 which was then inserted into the BamHl /Nrul site in the linker region of pMTL22p (Chambers et al., 1988) .
Site-directed mutagenesis was performed on L-asparaginase DNA cloned into M13mp8 (Sambrook et al., 1989) . Oligodeoxyribonucleotides for use as sequencing primers and in site-directed mutagenesis were synthesized using an Applied Biosystems Model 380A DNA synthesizer. The three oligonucleotides for each of the mutations P285T, P286Q and E288A were: 5'-GG TAT TGT GAC GCC GGA TG-3' 5'-T TGT GCC GCA GGA TGA AGA-3' 5'-C GCC GGA TGC AGA GCT GC-3' Site-directed mutagenesis to produce the single mutations was performed on single-stranded recombinant M13 template DNA by the primer-extension method as described by Carter et al. (1985) . Double-stranded phage DNA containing the Lasparaginase gene was digested with Sall/Nrul and a 0.9 kb fragment, containing the mutation, was isolated by agarose-gel electrophoresis. This DNA fragment containing the mutation was used to replace a similar fragment from the wild-type gene by subcloning in the vector pASN410. The vector pASN410 was derived from pASN400, which was constructed by replacing the wild-type 0.9 kb Sall/Nrul fragment of L-asparaginase with peptides were screened for binding to antibody as described in linker oligonucleotides designed to ligate the Sall/Nrul sites. The presence of the mutations, and the absence of spurious mutations, in the 0.9 kb insert were confirmed by DNA sequencing using the dideoxy-chain-termination method of Sanger et al. (1977) .
Enzyme purification Recombinant Er. chrysanthemi L-asparaginase expressed in E. coli was purified by a modification of the method of Goward et al. (1992) . Protein from the cell extract in 40 mM sodium phosphate, pH 6.0, was purified by cation-exchange chromatography on a Mono-S HR 10/10 column (10 cm x 1 cm) (Pharmacia). Bound protein was eluted with 40 mM sodium phosphate, pH 6.8.
Enzyme activity L-Asparaginase activity was determined using a Technicon Autoanalyser as described by Wade and Phillips (1971) , but incorporating the Berthelot colour reaction (Gordon et al., 1978) . One unit of L-asparaginase was defined as 1 ,umol of NH3 produced/min at 37 'C. Protein concentrations were determined by the Folin method of Lowry et al. (1951) , with BSA as standard. Column eluates were monitored by measuring the A280. Kinetic constants" were determined in duplicate, and were calculated by non-linear regression analysis using the program ENZFITTER (Biosoft, Cambridge, U.K.).
Gel electrophoresis
The purity of L-asparaginase was determined by SDS/PAGE using a PhastGel apparatus (Pharmacia) and 10-15 % acrylamide PhastGels stained with Coomassie Brilliant Blue R250. The Mr of L-asparaginase was compared with that of low-Mr markers (Pharmacia). The pI values of the enzymes were determined using Servalyt-Precotes (Serva, Heidelberg, Germany), with a pH range of 3-10, according to the supplier's instructions. pl values were compared with markers in the pH range 3-9.5 (BioRad).
RESULTS AND DISCUSSION Epitope mapping Ten continuous epitopes were identified when overlapping hexapeptides spanning the entire L-asparaginase sequence were allowed to bind polyclonal antibodies (Figure 1 ). These antibodies were raised against the native enzyme in two rabbits (RpAb 1 and RpAb 2) and two mice (MpAb 1 and MpAb 2). Some of the sites included multiple overlapping determinants, whereas residues 282-292 near the C-terminus of the protein represented an immunodominant epitope to which most of the immune response was directed. Residues 285PPDEE289 were vommon to all overlapping epitopes in the region 282-292. The immunodominant region was unique to the Er. chrysanthemi enzyme, since rabbit polyclonal antibodies raised against E. coli L-asparaginase did not bind peptides in that region (Figure 2 ). Four epitopes were identified with antibodies raised against the E. coli enzyme. They corresponded to 37DTLI40, 84DDVDGV89, 208VFDVRG213 and 255V5VRG1260. Two of these epitopes, residues 37-40 and 208-213 were also recognized by polyclonal antibodies raised against the Er. chrysanthemi enzyme. This cross-reactivity may be due to structural similarities between the two enzymes, since both have similar amino acid sequences, with 42 % of the residues being identical (Maita and Matsuda, 1980; Minton et al., 1986) . The cross-reacting epitopes may also contain regions of antigenic equivalence. Sequence alignments indicate that the epitope 37DTL140 of the Er. chysanthemi enzyme sequence corresponds to 33ENLV36 in the F. coli enzyme. Similarly, for the epitope 205VFDVR212 the corresponding sequence in the E. coli enzyme is '99PFDVS203. Cross-reaction may also have occurred due to the multispecificity of the antibodycombining sites.
Verfflcation of the immunodominant region using a free peptide "2GIVPPDEELPG292 In e.i.i.s.a.
A free peptide spanning the immunodominant epitope bound polyclonal antibodies raised against both native Er. chrysanthemi L-asparaginase and against the peptide (Figure 3) 
Replacement-net analysis
The contribution of each amino acid residue within the immunodominant region for binding to the antibody was studied. All the residues in each of two hexapeptide sequences 283IVPPDE288 and 287DEELPG292 were sequentially replaced with the other 19 naturally occurring amino acids (Figures 4 and  5) . Overall, those residues within peptide 2831IVPPDE288 that were essential for recognition by the rabbit and mouse polyclonal antibodies were Pro28' and Pro286 (Figure 4) . Replacement of each of these residues by most of the other amino acids resulted in binding being reduced to less than 50 % of that of the parent peptide. Similarly, Pro29' in peptide 287DEELPG292 was essential for binding to the antibodies, whereas some substitutions for each of the residues in the sequence 287DEEL290 and for Gly292
showed decreased binding to the antibodies ( Figure 5 ). Those amino acid replacements that reduced binding of the peptide to the antibody were change of charge, or aromatic hydrophobic to aliphatic hydrophobic, or a small residue to a large residue.
Site-directed mutagenesis
The mutations P285T, P286Q and E288A in the immunodominant region were selected, since the replacement residues were those present in corresponding positions in the E. coli Lasparaginase sequence (Bonthron et al., 1990 chosen, since they were critical for binding to the antibodies from the replacement-net analysis, whilst Glu288 was chosen as a control, since its effect on binding the antibodies was relatively neutral.
Enzyme characterization
The mutant enzymes were purified by cation-exchange chromatography in a similar manner to the recombinant wildtype enzyme. High yields of purified enzyme were obtained for the enzymes P285T (64%), P2186Q (68 %) and E288A (94%). The purified enzymes had subunit Mr values of 35000, which were identical with that obtained for the wild-type enzyme. The subunit Mr of the E. coli enzyme was also 35000. The pI values of the recombinant wild-type, P285T and P286Q enzymes were 8.6, and that for the E288A enzyme was 9.2. The pl of the E. coli enzyme was 4.9 and was similar to the reported value (Labourer et al., 1971 
Antigenic characterization
Binding of the mutant enzymes to antibodies raised against the wild-type enzyme was studied by sandwich e.l.i.s.a. (Figure 6 ). Lower binding compared with the wild-type enzyme indicated reduced antigenicity. The mutation P285T reduced the antigenicity of L-asparaginase by 8-fold compared with the wild-type enzyme, whilst P286Q and E288A reduced the antigenicity of Lasparaginase by 2-and 1.5-fold respectively. These results were typical for two monoclonal antibodies raised against the wildtype enzyme and was reproducible for a set of six duplicate experiments. The X-ray crystal structure of E. coli L-asparaginase has been recently determined (Swain et al., 1993 (0.2-3.0 ng -ml-'). The amount of antigen that bound was detected with rabbit polyclonal antibodies (diluted 1:500) raised against the native enzyme for further quantification. 0, Wildtype enzyme; *, mutant E288A; *, mutant P286Q; *, mutant P285T.
The mutation P285T caused the greatest reduction in antigenicity of the enzyme, and may therefore be most useful in further studies aimed at evaluating the use of antigenically modified enzymes for therapy. We thank Dr. Stuart Clark for raising antibodies and Dr. Richard Seabrook and Dr. Stuart Clark for helpful discussions during the course of this work.
